Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma
Adding the bispecific antibody epcoritamab to rituximab and lenalidomide (R2) provides great overall responses in patients with high-risk follicular lymphoma. This is one of the conclusions that MD and PhD, Anna Sureda Balari, presented at this year’s EHA 2023 congress. Let her elaborate on her findings in this MEDtalk.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.